These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37497426)

  • 1. Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale.
    Shaw JR; Unachukwu U; Cyr J; Siegal DM; Castellucci LA; Dreden PV; Dowlatshahi D; Buyukdere H; Ramsay T; Carrier M
    TH Open; 2023 Jul; 7(3):e229-e240. PubMed ID: 37497426
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
    Brinkman HJM; Zuurveld M; Meijers JCM
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.
    Chuck CC; Kim D; Kalagara R; Rex N; Madsen TE; Mahmoud L; Thompson BB; Jones RN; Furie KL; Reznik ME
    Neurology; 2021 Nov; 97(21):e2054-e2064. PubMed ID: 34556569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding.
    Korobey MJ; Sadaka F; Javed M; Moynihan M; Alsaei A
    Neurocrit Care; 2021 Feb; 34(1):112-120. PubMed ID: 32430804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
    White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
    Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding.
    Jaspers T; Shudofsky K; Huisman MV; Meijer K; Khorsand N
    Res Pract Thromb Haemost; 2021 May; 5(4):e12518. PubMed ID: 34084991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.
    Bavalia R; Abdoellakhan R; Brinkman HJM; Brekelmans MPA; Hamulyák EN; Zuurveld M; Hutten BA; Westerweel PE; Olie RH; Ten Cate H; Kruip M; Middeldorp S; Meijer K; Coppens M
    Res Pract Thromb Haemost; 2020 May; 4(4):569-581. PubMed ID: 32548555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.
    Lu G; Lin J; Bui K; Curnutte JT; Conley PB
    Res Pract Thromb Haemost; 2020 Nov; 4(8):1282-1294. PubMed ID: 33313467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations.
    Dinunno CV; Lopez CN; Succar L; Nguyen DT; Graviss EA; Salazar E; Donahue KR
    Pharmacotherapy; 2022 Oct; 42(10):768-779. PubMed ID: 36054446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.
    Shaw JR; Castellucci LA; Siegal D; Carrier M
    J Thromb Haemost; 2023 Mar; 21(3):433-452. PubMed ID: 36696204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
    Luo C; Chen F; Chen YH; Zhao CF; Feng CZ; Liu HX; Luo DZQ
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2637-2653. PubMed ID: 33829451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
    Coleman CI; Dobesh PP; Danese S; Ulloa J; Lovelace B
    Future Cardiol; 2021 Jan; 17(1):127-135. PubMed ID: 32618210
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
    Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
    Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.